LysaKare

RSS

arginine / lysine

Authorised
This medicine is authorised for use in the European Union.

Overview

LysaKare is a medicine used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium (177Lu) oxodotreotide.

LysaKare is for use in adults and contains the active substances arginine and lysine.

This EPAR was last updated on 23/06/2022

Authorisation details

Product details
Name
LysaKare
Agency product number
EMEA/H/C/004541
Active substance
  • L-arginine hydrochloride
  • L-lysine hydrochloride
International non-proprietary name (INN) or common name
  • arginine
  • lysine
Therapeutic area (MeSH)
Radiation Injuries
Anatomical therapeutic chemical (ATC) code
V03AF11
Publication details
Marketing-authorisation holder
Advanced Accelerator Applications
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
25/07/2019
Contact address

20 rue Diesel
01630 Saint Genis Pouilly
France

Product information

23/06/2022 LysaKare - EMEA/H/C/004541 - N/0010

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Detoxifying agents for antineoplastic treatment

Therapeutic indication

LysaKare is indicated for reduction of renal radiation exposure during Peptide-Receptor Radionuclide Therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.

Assessment history

How useful was this page?

Add your rating
Average
1 rating